CN1953990A - 具有抗－整联蛋白活性的环肽衍生物 - Google Patents

具有抗－整联蛋白活性的环肽衍生物 Download PDF

Info

Publication number
CN1953990A
CN1953990A CNA2005800152380A CN200580015238A CN1953990A CN 1953990 A CN1953990 A CN 1953990A CN A2005800152380 A CNA2005800152380 A CN A2005800152380A CN 200580015238 A CN200580015238 A CN 200580015238A CN 1953990 A CN1953990 A CN 1953990A
Authority
CN
China
Prior art keywords
phe
gly
asp
arg
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800152380A
Other languages
English (en)
Chinese (zh)
Inventor
A·达尔波佐
S·潘克
G·加尼尼
M·O·廷蒂
C·皮萨诺
L·维西
倪明红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN1953990A publication Critical patent/CN1953990A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800152380A 2004-05-13 2005-05-04 具有抗－整联蛋白活性的环肽衍生物 Pending CN1953990A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000239A ITRM20040239A1 (it) 2004-05-13 2004-05-13 Derivati ciclopeptidici ad attivita' antintegrine.
ITRM2004A000239 2004-05-13

Publications (1)

Publication Number Publication Date
CN1953990A true CN1953990A (zh) 2007-04-25

Family

ID=34968013

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800152380A Pending CN1953990A (zh) 2004-05-13 2005-05-04 具有抗－整联蛋白活性的环肽衍生物

Country Status (23)

Country Link
US (1) US20070178045A1 (https=)
EP (1) EP1751176B1 (https=)
JP (1) JP2008500971A (https=)
KR (1) KR20070012524A (https=)
CN (1) CN1953990A (https=)
AR (1) AR048957A1 (https=)
AT (1) ATE460426T1 (https=)
AU (1) AU2005243418A1 (https=)
BR (1) BRPI0510985A (https=)
CA (1) CA2562576A1 (https=)
CY (1) CY1110039T1 (https=)
DE (1) DE602005019876D1 (https=)
DK (1) DK1751176T3 (https=)
ES (1) ES2340862T3 (https=)
HR (1) HRP20100301T1 (https=)
IT (1) ITRM20040239A1 (https=)
MX (1) MXPA06012887A (https=)
PL (1) PL1751176T3 (https=)
PT (1) PT1751176E (https=)
RS (1) RS51300B (https=)
SI (1) SI1751176T1 (https=)
TW (1) TW200606178A (https=)
WO (1) WO2005111064A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022183360A1 (en) * 2021-03-02 2022-09-09 Tsao Yeou Ping Short synthetic peptide and their uses for treating dry eye disease

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI426905B (zh) * 2006-02-09 2014-02-21 安龍製藥公司 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
EP1961759A1 (en) * 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
TWI474819B (zh) 2012-05-15 2015-03-01 國立成功大學 調控物及含有該調控物之醫藥組合物
HK1219740A1 (zh) * 2013-03-15 2017-04-13 Biogen Ma Inc. 使用抗αVβ5抗体治疗和预防急性肾损伤
CN103588863B (zh) * 2013-11-15 2016-08-17 苏州强耀生物科技有限公司 Rgd环肽合成制备工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
DE19725368A1 (de) * 1997-06-16 1998-12-17 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022183360A1 (en) * 2021-03-02 2022-09-09 Tsao Yeou Ping Short synthetic peptide and their uses for treating dry eye disease

Also Published As

Publication number Publication date
DK1751176T3 (da) 2010-06-14
AU2005243418A1 (en) 2005-11-24
ATE460426T1 (de) 2010-03-15
ITRM20040239A1 (it) 2004-08-13
EP1751176A1 (en) 2007-02-14
MXPA06012887A (es) 2007-02-15
KR20070012524A (ko) 2007-01-25
EP1751176B1 (en) 2010-03-10
RS51300B (sr) 2010-12-31
DE602005019876D1 (de) 2010-04-22
PT1751176E (pt) 2010-05-12
CY1110039T1 (el) 2012-05-23
AR048957A1 (es) 2006-06-14
CA2562576A1 (en) 2005-11-24
WO2005111064A8 (en) 2006-02-09
BRPI0510985A (pt) 2007-12-04
ES2340862T3 (es) 2010-06-10
HRP20100301T1 (hr) 2010-06-30
TW200606178A (en) 2006-02-16
JP2008500971A (ja) 2008-01-17
US20070178045A1 (en) 2007-08-02
SI1751176T1 (sl) 2010-06-30
WO2005111064A1 (en) 2005-11-24
PL1751176T3 (pl) 2010-08-31

Similar Documents

Publication Publication Date Title
JP7289158B2 (ja) Ｉｌ－２受容体結合化合物
TW580501B (en) Heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
CN104784699A (zh) 叶酸受体结合配体-药物偶联物
EP1077218B1 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
BR122019016211B1 (pt) Composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo
CA2267328A1 (en) Glycoconjugates from modified camptothecin derivates (20-o-linkage)
AU744425B2 (en) 20(s) camptothecin glycoconjugates
EP2764010B1 (en) Template-fixed peptidomimetics as inhibitors of fpr1
US20020068695A1 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
CN1953990A (zh) 具有抗－整联蛋白活性的环肽衍生物
US20020173468A1 (en) Modified cytostatic agents
SK173599A3 (en) Cyclic azapeptides with angiogenic effect
JP2000264900A (ja) 新規生理活性ペプチド
CN107602450B (zh) 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用
EP1961759A1 (en) Integrin targeted cyclopeptide ligands, their preparation and use
HK1104045A (en) Cyclopeptide derivatives with anti-integrin activity
WO2004005328A2 (en) Peptidomimetic compound useful as inhibitor of integrins
JP7307500B2 (ja) Ｉｌ－２受容体結合化合物
JPH06306096A (ja) ペプチド誘導体及びその用途
CN101010103A (zh) 在20位与整联蛋白拮抗剂缀合的喜树碱衍生物
AU2021201047B2 (en) Il-2 receptor binding compounds
CN112010940A (zh) 抑制pd-1/pd-l1的大环化合物及其应用
WO2004069861A1 (de) Peptidische sulfonamide
Parente Diketopiperazines as scaffold for the synthesis of new compounds modulating protein-protein interactions and functions
JPH0717999A (ja) ペプチド誘導体及びその用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1104045

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070425

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1104045

Country of ref document: HK